Search research articles
Contact Us
Filters
Showing results (81-90 of 672) with videos related to
Page
of 68
Sort By:
Journal of Clinical Hypertension (Greenwich, Conn.)
|
October 12, 2007
Blood pressure reduction appears more important than specific antihypertensive agent used to improve diastolic function
Michael J Bloch, Jan Basile
Journal of Clinical Hypertension (Greenwich, Conn.)
|
August 19, 2007
AHA scientific statement: new blood pressure targets for high-risk and established coronary artery disease patients
Michael J Bloch, Jan Basile
Journal of Clinical Hypertension (Greenwich, Conn.)
|
November 21, 2007
Development of new-onset diabetes mellitus is associated with an increased risk for cardiac morbidity: the VALUE Trial
Michael J Bloch, Jan Basile
Rheumatology
|
January 1, 1970
Mast cells and mast cell-sensitizing (homocytotropic) antibodies
K J Bloch, C Angevine
Journal of Clinical Hypertension (Greenwich, Conn.)
|
July 4, 2012
What should be the target blood pressure in patients with chronic kidney disease? Data from the Kidney Early Evaluation Program
Michael J Bloch, Jan Basile
The Journal of Biological Chemistry
|
November 22, 2002
The hydrophilic domain of small ankyrin-1 interacts with the two N-terminal immunoglobulin domains of titin
Aikaterini Kontrogianni-Konstantopoulos, Robert J Bloch
The Journal of Comparative Neurology
|
September 22, 1988
Estrogen/progesterone treatment in adulthood affects the size of several components of the medial preoptic area in the male rat
G J Bloch, R A Gorski
Journal of Muscle Research and Cell Motility
|
October 26, 1999
Differential distribution of dystrophin and beta-spectrin at the sarcolemma of fast twitch skeletal muscle fibers
M W Williams, R J Bloch
Journal of Clinical Hypertension (Greenwich, Conn.)
|
October 30, 2010
Combination angiotensin receptor blocker-neutral endopeptidase inhibitor provides additive blood pressure reduction over angiotensin receptor blocker alone
Michael J Bloch, Jan N Basile
Vascular Health and Risk Management
|
June 22, 2007
Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data
Kirk A Bronander, Michael J Bloch
Page
of 68
Search research articles
Search
Showing results (81-90 of 672) with videos related to
Sort By:
Page
of 68
Journal of Clinical Hypertension (Greenwich, Conn.)
|
October 12, 2007
Blood pressure reduction appears more important than specific antihypertensive agent used to improve diastolic function
Michael J Bloch, Jan Basile
Journal of Clinical Hypertension (Greenwich, Conn.)
|
August 19, 2007
AHA scientific statement: new blood pressure targets for high-risk and established coronary artery disease patients
Michael J Bloch, Jan Basile
Journal of Clinical Hypertension (Greenwich, Conn.)
|
November 21, 2007
Development of new-onset diabetes mellitus is associated with an increased risk for cardiac morbidity: the VALUE Trial
Michael J Bloch, Jan Basile
Rheumatology
|
January 1, 1970
Mast cells and mast cell-sensitizing (homocytotropic) antibodies
K J Bloch, C Angevine
Journal of Clinical Hypertension (Greenwich, Conn.)
|
July 4, 2012
What should be the target blood pressure in patients with chronic kidney disease? Data from the Kidney Early Evaluation Program
Michael J Bloch, Jan Basile
The Journal of Biological Chemistry
|
November 22, 2002
The hydrophilic domain of small ankyrin-1 interacts with the two N-terminal immunoglobulin domains of titin
Aikaterini Kontrogianni-Konstantopoulos, Robert J Bloch
The Journal of Comparative Neurology
|
September 22, 1988
Estrogen/progesterone treatment in adulthood affects the size of several components of the medial preoptic area in the male rat
G J Bloch, R A Gorski
Journal of Muscle Research and Cell Motility
|
October 26, 1999
Differential distribution of dystrophin and beta-spectrin at the sarcolemma of fast twitch skeletal muscle fibers
M W Williams, R J Bloch
Journal of Clinical Hypertension (Greenwich, Conn.)
|
October 30, 2010
Combination angiotensin receptor blocker-neutral endopeptidase inhibitor provides additive blood pressure reduction over angiotensin receptor blocker alone
Michael J Bloch, Jan N Basile
Vascular Health and Risk Management
|
June 22, 2007
Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data
Kirk A Bronander, Michael J Bloch
Page
of 68